Skip to main content

Table 2 The role of m6A-binding proteins in human solid cancers and hematological malignancy

From: m6A-binding proteins: the emerging crucial performers in epigenetics

Cancers

m6A readers

Target RNAs

Mechanism

Reference

Hepatocellular carcinoma

YTHDF1

Snail

Accelerating the translation of Snail mRNA

[47]

YTHDF2

EGFR

Destabilizing EGFR mRNA

[42]

YTHDF2

IL-11, SERPINE2

Increasing the degradation of IL-11 and SERPINE2 mRNAs

[43]

YTHDF2

SOCS2

Facilitating SOCS2 mRNA decay

[44]

IGF2BP1/2/3

MYC

Enhancing the expression of MYC mRNA

[32]

IGF2BP1

SRF

Promoting SRF mRNA translation

[48]

Colorectal cancer

YTHDF1

β-catenin, WNT6, FZD9

Increasing the expression of β-catenin, WNT6 and FZD9A to activate Wnt/β-catenin pathway

[49]

YTHDF3

GAS5

Enhancing the degradation of lncRNA GAS5

[50]

YTHDC1

circNSUN2

Facilitating circNSUN2 export from nucleus to cytoplasm

[51]

IGF2BP2

HMGA2

Forming a circNSUN2/IGF2BP2 complex to fortify the stability of HMGA2

[51]

IGF2BP2

SOX2

Stabilizing SOX2 mRNA

[52]

Gastric cancer

IGF2BP1

SEC62

Augmenting SEC62 mRNA translation

[53]

IGF2BP3

HDGF

Facilitating HDGF mRNA expression

[54]

HuR

ZMYM1

Fortifying the stability of ZMYM1 mRNA

[116]

Lung cancer

YTHDF1

CDK2, CDK4, cyclinD1

Promoting the translations of CDK2, CDK4 and cyclinD1

[56]

YTHDF1

Keap1

Leading to cisplatin resistance of tumor cells via modulating the Keap1-Nrf2-AKR1C1 axis

[56]

YTHDF1/3

YAP

Up-regulating YAP expression

[57]

YTHDF2

6PGD

Facilitating 6PGD degradation

[55]

YTHDF3

MALAT1

Increasing MALAT1 stability

[57]

MELLT3

EGFR, TAZ

Accelerating the translation of EGFR and TAZ

[58]

Bladder cancer

YTHDF1/3

ITGA6

Promoting ITGA6 mRNA translation

[59]

YTHDF1

CDCP1

Enhancing the expression of CDCP1 mRNA

[60]

MELLT3

CDCP1

Facilitating CDCP1 translation and strengthening the binding of YTHDF1 to CDCP1

[60]

Endometrial cancer

YTHDF1

PHLPP2

Increasing the expression of PHLPP2

[61]

YTHDF2

PRR5, PRR5L, mTOR

Diminishing the abundance of PRR5, PRR5L, and mTOR

[61]

Ovarian cancer

YTHDF1

EIF3C

Targeting at EIF3C to enhance its translation efficiency

[62]

Cervical cancer

YTHDF2

GAS5

Abrogating the GAS5 expression

[63]

Melanoma

YTHDF2

PD-1 (PDCD1), CXCR4, SOX10

Downregulating the mRNA and protein levels of three key intrinsic pro-tumorigenic factors, including PD-1 (PDCD1), CXCR4 and SOX10

[64]

YTHDF1

HINT2

Promoting the translation of HINT2 mRNA

[65]

Breast cancer

YTHDF2

BNIP3

Facilitating the degradation of BNIP3 mRNA

[66]

Pancreatic cancer

IGF2BP2

DANCR

Enhancing the DANCR expression

[67]

Acute myeloid leukemia

YTHDF2

TNFR2

Reducing the TNFR2 expression

[81]

YTHDF2

MYC, CEBPA

Accelerating the decay of MYC and CEBPA

[82]